Resilience forges JV with MD Anderson, readying new cell therapies for cancer
The University of Texas MD Anderson Cancer Center and contract biologic manufacturer Resilience are cracking open a new partnership, seeking to accelerate the development and manufacturing of cell therapies for cancer patients.
The so-called Cell Therapy Manufacturing Center will be based in a 60,000-square-foot facility in downtown Houston. With a team of 70 employees, the center will focus on process and analytical development as well as early-phase and clinical-stage GMP.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.